Jenesis Innovative Research Awards™


Statement of Purpose

The Jenesis Innovative Research Awards provide support to United States (US)-based investigators who are engaged in innovative research that will advance scientific knowledge and enhance patient care in pulmonary arterial hypertension (PAH). Applicants must be part of an appropriate research group and under the supervision of a qualified mentor. Three awards will be issued annually.

 

Award Amount

$100,000

 

Award Duration

1 year

 

Timeline

Application Deadline: June 30, 2019

Applicant Notification: September 16, 2019

Awards Dinner: October 20, 2019

 

Types of Awards

Jenesis Outcomes Award™

Jenesis Clinical Award™

Jenesis Pre-Clinical Award™

 

Note: Applications must be completed online and submitted electronically. Please have all application components complete and ready to submit. You will not be able to save and return to your application.

Available grants include:

  • Jenesis Outcomes Award™

    Exploring the science of clinical or patient-reported outcomes research.

  • Jenesis Clinical Award™

    Exploring treatment of unmet populations or novel treatment approaches

  • Jenesis Preclinical Award™

    Exploring the mechanistic benefits of prostacyclin-class therapy through translational research

Applicant Eligibility

At the time of proposal submission, applicants must meet the following requirements:

  • Hold a PhD degree or equivalent, or a doctoral-level clinical degree, such as MD, DO, or PharmD
  • Be a US citizen, permanent resident, or hold a valid nonimmigrant visa
  • Be within five years from completion of final training in association with an academic research institution in the US at the time of the application
  • Demonstrate a strong career interest in PAH
  • Have at least 50% protected time to devote to research (instead of administrative or clinical duties that are not part of the research)
  • May be the recipient of a career development award (K or equivalent), but not an R category grant
  • Must propose a novel project. Funding from other sources (government or industry) for another project with significant scientific or financial overlap will disqualify the applicant
  • Be able to complete the research within the 1-year award period
  • Will have an academic appointment at the institution where the research will be conducted at the time of the award

Scientific Review Committee (SRC)

An independent SRC, made up of experts in the field of PAH, will assess applications based on their scientific merit, originality, feasibility, and potential impact in the field of PAH.

 

Ioana R. Preston, MD, Chairman

Associate Professor

Director, Pulmonary Hypertension Center

Tufts University School of Medicine

Boston, MA

 

Review Committee

Stephen Chan, MD, PhD, FAHA

Associate Professor of Medicine, Division of Cardiology

Director, Center for Pulmonary, Vascular Biology and Medicine

Associate Program Director–Fellowship Research, Cardiology

Vascular Medicine Institute

University of Pittsburgh

Pittsburgh, PA

 

Harrison W. Farber, MD

Professor of Medicine

Tufts University School of Medicine

Boston, MA

 

Mardi Gomberg-Maitland

Director of the Pulmonary Hypertension Program

Professor of Medicine

George Washington University

Washington, DC

 

Anna Ryan Hemnes, MD

Associate Professor

Division of Allergy, Pulmonary and Critical Care Medicine

Vanderbilt University School of Medicine

Nashville, TN

 

Steven M. Kawut, MD, MS

Director, Pulmonary Hypertension/Pulmonary Vascular Disease Program

Professor of Medicine

Professor of Biostatistics and Epidemiology

University of Pennsylvania

Philadelphia, PA

 

For additional information or to submit an application, please visit UTJenesisAwards.com. Should you have difficulty with your application submission, please call 646-674-1820 and ask for the Jenesis Research Program Coordinator. For questions about this program, please email UTJenesisAwards@contacthmc.com.

About
Martine and Bina Rothblatt founded United Therapeutics when their daughter Jenesis was diagnosed with PAH as a young girl. Faced with a stunning lack of information, support, and treatment options, they became committed to providing better therapies and eventually a cure for this disease. Jenesis and her story remain the inspiration behind United Therapeutics and the motivation for the Jenesis Innovative Research Awards, designed to award junior investigators dedicated to medical advancement for pulmonary hypertension through independent clinical, preclinical, and outcomes-based research.